Catalent Inc (NASDAQ:CTLT) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Wednesday.

CTLT has been the topic of several other research reports. Bank of America Corporation reiterated a “buy” rating and issued a $38.00 price target (up previously from $37.00) on shares of Catalent in a report on Friday, July 21st. Zacks Investment Research upgraded Catalent from a “sell” rating to a “buy” rating and set a $39.00 price target on the stock in a report on Tuesday, July 4th. William Blair upgraded Catalent from a “market perform” rating to an “outperform” rating in a report on Monday, May 15th. Finally, TheStreet upgraded Catalent from a “c” rating to a “b-” rating in a report on Wednesday, April 19th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $32.00.

Catalent (NASDAQ:CTLT) traded down 0.03% during trading on Wednesday, hitting $35.30. The stock had a trading volume of 371,171 shares. The firm has a market capitalization of $4.41 billion and a P/E ratio of 41.58. The stock has a 50 day moving average of $35.23 and a 200 day moving average of $32.03. Catalent has a one year low of $21.83 and a one year high of $38.73.

ILLEGAL ACTIVITY NOTICE: “Catalent Inc (CTLT) Upgraded by BidaskClub to Hold” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/16/catalent-inc-ctlt-upgraded-by-bidaskclub-to-hold.html.

In other Catalent news, SVP Christine Dolan sold 745 shares of the stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $34.85, for a total value of $25,963.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Several hedge funds and other institutional investors have recently bought and sold shares of CTLT. Flinton Capital Management LLC raised its position in Catalent by 17.7% in the first quarter. Flinton Capital Management LLC now owns 3,616 shares of the company’s stock worth $102,000 after buying an additional 544 shares in the last quarter. Acrospire Investment Management LLC raised its position in Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. Quantbot Technologies LP raised its position in Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after buying an additional 1,804 shares in the last quarter. Meadow Creek Investment Management LLC raised its position in Catalent by 17.7% in the first quarter. Meadow Creek Investment Management LLC now owns 4,972 shares of the company’s stock worth $141,000 after buying an additional 748 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Catalent by 115.7% in the first quarter. Acadian Asset Management LLC now owns 5,847 shares of the company’s stock worth $166,000 after buying an additional 3,136 shares in the last quarter.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.